See more : Biora Therapeutics, Inc. (PROG) Income Statement Analysis – Financial Results
Complete financial analysis of KORU Medical Systems, Inc. (KRMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of KORU Medical Systems, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Izumi Co., Ltd. (8273.T) Income Statement Analysis – Financial Results
- Yamaha Corporation (YAMCF) Income Statement Analysis – Financial Results
- BingEx Limited (FLX) Income Statement Analysis – Financial Results
- Rolex Rings Limited (ROLEXRINGS.NS) Income Statement Analysis – Financial Results
- Henan Senyuan Electric Co., Ltd. (002358.SZ) Income Statement Analysis – Financial Results
KORU Medical Systems, Inc. (KRMD)
About KORU Medical Systems, Inc.
KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.52M | 27.90M | 23.49M | 24.18M | 23.16M | 17.35M | 15.98M | 12.29M | 12.25M | 11.24M | 8.70M | 7.76M | 6.39M | 4.92M | 3.77M | 3.44M | 2.35M | 1.73M | 1.75M | 1.56M | 1.53M | 1.66M | 1.76M | 2.09M | 2.07M |
| Cost of Revenue | 11.81M | 12.53M | 9.72M | 9.24M | 8.31M | 6.54M | 6.52M | 4.72M | 4.64M | 4.56M | 3.39M | 2.82M | 2.25M | 1.66M | 1.26M | 1.24M | 899.98K | 663.51K | 728.52K | 726.46K | 723.56K | 959.54K | 1.33M | 1.11M | 1.13M |
| Gross Profit | 16.71M | 15.37M | 13.77M | 14.94M | 14.85M | 10.81M | 9.46M | 7.57M | 7.60M | 6.69M | 5.31M | 4.94M | 4.14M | 3.26M | 2.51M | 2.20M | 1.45M | 1.07M | 1.02M | 833.76K | 804.83K | 697.02K | 427.94K | 978.94K | 939.85K |
| Gross Profit Ratio | 58.59% | 55.09% | 58.62% | 61.78% | 64.13% | 62.29% | 59.20% | 61.57% | 62.08% | 59.47% | 61.04% | 63.69% | 64.77% | 66.32% | 66.53% | 63.85% | 61.67% | 61.75% | 58.27% | 53.44% | 52.66% | 42.08% | 24.33% | 46.93% | 45.50% |
| Research & Development | 5.74M | 4.96M | 2.47M | 1.30M | 740.48K | 241.12K | 60.70K | 237.49K | 207.28K | 468.15K | 218.15K | 147.58K | 90.33K | 35.52K | 27.92K | 22.44K | 59.93K | 42.03K | 41.82K | 44.03K | 42.19K | 40.27K | 40.84K | 35.34K | 80.94K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.37M | 20.61M | 17.86M | 12.03M | 9.77M | 8.20M | 7.91M | 7.77M | 5.94M | 4.79M | 3.85M | 3.54M | 2.66M | 1.97M | 1.70M | 1.31M | 1.13M | 993.42K | 984.63K | 1.07M | 876.39K | 827.87K | 635.53K | 827.99K | 1.01M |
| Other Expenses | 870.39K | 0.00 | 679.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -9.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 26.98M | 26.15M | 20.80M | 13.74M | 10.85M | 8.75M | 7.97M | 8.31M | 6.42M | 5.54M | 4.30M | 3.88M | 2.85M | 2.07M | 1.79M | 1.42M | 1.25M | 1.09M | 1.11M | 1.19M | 1.05M | 949.57K | 802.20K | 1.08M | 1.18M |
| Cost & Expenses | 38.79M | 38.68M | 30.52M | 22.98M | 19.16M | 15.29M | 14.49M | 13.03M | 11.07M | 10.10M | 7.69M | 6.70M | 5.10M | 3.73M | 3.05M | 2.66M | 2.15M | 1.76M | 1.83M | 1.92M | 1.77M | 1.91M | 2.13M | 2.19M | 2.30M |
| Interest Income | 561.33K | 145.59K | 13.08K | 42.40K | 80.66K | 28.10K | 0.00 | 2.94K | 0.00 | 5.62K | 7.43K | 8.08K | 12.85K | 8.72K | 1.35K | 8.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.89K | 3.41K | 512.00 | 4.55K | 28.28K | 31.54K | 36.39K | 47.50K | 51.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 870.39K | 587.14K | 463.13K | 418.60K | 340.23K | 309.26K | 308.71K | 300.61K | 271.57K | 283.88K | 232.96K | 190.97K | 103.98K | 65.77K | 64.80K | 79.36K | 68.20K | 60.43K | 79.09K | 81.82K | 80.55K | 81.44K | 84.84K | 84.97K | 87.80K |
| EBITDA | -9.40M | -10.19M | -6.57M | 1.61M | 4.34M | 2.37M | 1.88M | -474.20K | 1.42M | 1.36M | 1.24M | 1.25M | 1.42M | 1.30M | 774.76K | 855.89K | 261.71K | 38.29K | -9.16K | -277.54K | -165.09K | -171.12K | -289.42K | -17.38K | -149.54K |
| EBITDA Ratio | -32.96% | -36.40% | -27.84% | 16.71% | 33.36% | 18.94% | 11.22% | -3.52% | 11.79% | 12.78% | 14.35% | 16.25% | 22.00% | 26.37% | 20.87% | 24.96% | 11.15% | 12.28% | 4.55% | -17.79% | -7.44% | -10.33% | -14.12% | 5.54% | -26.45% |
| Operating Income | -10.27M | -10.78M | -7.03M | -1.25M | 585.68K | 1.16M | 1.48M | -736.25K | 1.18M | 1.15M | 1.01M | 1.06M | 1.29M | 1.19M | 721.52K | 779.01K | 193.51K | -22.14K | -88.25K | -359.35K | -245.64K | -252.56K | -374.26K | -102.35K | -237.34K |
| Operating Income Ratio | -36.01% | -38.65% | -29.93% | -5.19% | 2.53% | 6.71% | 9.29% | -5.99% | 9.65% | 10.20% | 11.58% | 13.68% | 20.17% | 24.28% | 19.11% | 22.65% | 8.24% | -1.28% | -5.06% | -23.03% | -16.07% | -15.25% | -21.28% | -4.91% | -11.49% |
| Total Other Income/Expenses | 496.40K | 105.71K | 665.09K | 60.52K | 110.74K | 12.41K | 85.18K | -40.45K | -38.81K | -72.86K | 2.78K | -24.29K | -7.97K | -1.71K | -59.06K | -54.16K | -193.51K | -232.59K | -129.56K | -40.14K | -31.53K | -14.84K | -11.24K | -2.11K | 237.34K |
| Income Before Tax | -9.77M | -10.68M | -6.36M | -1.19M | 696.42K | 1.18M | 1.57M | -776.70K | 1.14M | 1.07M | 1.01M | 1.04M | 1.28M | 1.19M | 662.46K | 724.86K | 0.00 | -254.72K | -217.82K | -399.49K | -277.17K | -267.39K | -385.50K | -104.46K | 159.46K |
| Income Before Tax Ratio | -34.27% | -38.27% | -27.09% | -4.94% | 3.01% | 6.78% | 9.82% | -6.32% | 9.33% | 9.56% | 11.62% | 13.37% | 20.05% | 24.25% | 17.55% | 21.08% | 0.00% | -14.68% | -12.48% | -25.60% | -18.13% | -16.14% | -21.92% | -5.01% | 7.72% |
| Income Tax Expense | 3.97M | -2.01M | -1.80M | 17.80K | 132.07K | 266.38K | 483.08K | -241.70K | 359.71K | 321.42K | 307.02K | 312.35K | 465.29K | 489.03K | -226.98K | -306.00K | 196.01K | 232.59K | 129.56K | 1.40K | 831.00 | 800.00 | 572.00 | 2.11K | -487.64K |
| Net Income | -13.74M | -8.66M | -4.56M | -1.21M | 564.35K | 910.57K | 1.09M | -535.00K | 782.86K | 753.12K | 703.43K | 725.76K | 815.89K | 704.09K | 889.44K | 1.03M | -2.50K | -254.72K | -217.82K | -400.89K | -278.00K | -268.19K | -386.08K | -104.46K | 250.30K |
| Net Income Ratio | -48.18% | -31.05% | -19.42% | -5.01% | 2.44% | 5.25% | 6.80% | -4.35% | 6.39% | 6.70% | 8.09% | 9.35% | 12.77% | 14.31% | 23.56% | 29.97% | -0.11% | -14.68% | -12.48% | -25.69% | -18.19% | -16.19% | -21.95% | -5.01% | 12.12% |
| EPS | -0.30 | -0.19 | -0.10 | -0.03 | 0.01 | 0.02 | 0.03 | -0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.00 | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | -0.02 | 0.00 | 0.01 |
| EPS Diluted | -0.30 | -0.19 | -0.10 | -0.03 | 0.01 | 0.02 | 0.03 | -0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.00 | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | -0.02 | 0.00 | 0.01 |
| Weighted Avg Shares Out | 45.60M | 45.00M | 44.39M | 41.93M | 38.78M | 38.13M | 37.87M | 37.83M | 37.99M | 37.63M | 36.66M | 36.01M | 34.25M | 36.24M | 35.38M | 34.83M | 32.68M | 29.87M | 26.47M | 22.70M | 23.54M | 23.50M | 23.50M | 23.35M | 20.63M |
| Weighted Avg Shares Out (Dil) | 45.60M | 45.00M | 44.39M | 41.93M | 39.06M | 38.92M | 38.39M | 37.88M | 37.99M | 37.63M | 36.66M | 36.04M | 35.10M | 36.85M | 35.38M | 34.83M | 32.68M | 29.87M | 26.47M | 22.70M | 23.54M | 23.50M | 23.50M | 23.35M | 23.12M |
KORU Medical Systems to Report Third Quarter Financial Results on November 8, 2023
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients, today announced...
KORU Medical Systems to Present Two Abstracts at the Immunoglobulin National Society 2023 National Conference
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients,...
KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to Its Board of Directors
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients,...
KORU Medical Systems to Participate in the Gilmartin Group Emerging Growth Company Showcase
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients, today announced...
KORU Medical Systems, Inc. (KRMD) Q2 2023 Earnings Call Transcript
KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Linda Tharby - President and CEO Tom Adams - Chief Medical Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group...
KORU Medical Systems Inc. (KRMD) Reports Q2 Loss, Tops Revenue Estimates
KORU Medical Systems Inc. (KRMD) came out with a quarterly loss of $0.05 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.06 per share a year ago.
KORU Medical Systems, Inc. Announces 2023 Second Quarter Financial Results and Updates Full Year 2023 Outlook
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today...
KORU Medical Systems to Participate in the Genuity 43rd Annual Growth Conference
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients, today announced...
KORU Medical Systems, Inc. Announces Preliminary Second Quarter 2023 Revenues and Provides Business, Outlook and Executive Updates
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients,...
KORU Medical Systems to Report Second Quarter Financial Results on August 9, 2023
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients, today announced...
Source: https://incomestatements.info
Category: Stock Reports